Compounded semaglutide and tirzepatide are not FDA-approved preparations. In an October 30, 2026 warning letter to RonanRx, FDA challenged marketing that it said created misleading impressions about approval, who compounded the drugs and where their ingredients originated. 1

What did FDA object to in the RonanRx letter?

FDA challenged implied compounder identity, approval language and US-origin messaging. These are the agency’s findings about the specific advertising it reviewed, not a judgment about every telehealth platform. 1

The agency also said qualifying disclaimers did not correct the overall impression of the approval claims. That distinction matters when evaluating a page containing both a prominent promotional statement and a narrower qualification elsewhere. 1

Is a compounded drug the same as an approved generic?

No. FDA explains that an approved generic follows a defined approval pathway, including requirements relating to equivalence to the reference medicine. A compounded preparation does not go through that approval process. An ingredient appearing in an approved medicine is therefore not enough to establish approval of another preparation. 2

Compounding can still meet a medical need when an approved formulation is unsuitable, such as a required ingredient adjustment. That role and FDA approval are different questions. The absence of approval should not be rewritten as a claim that every instance of compounding is unlawful. 2

What does the letter say about manufacturing origin?

The origin concern relates to the distinction between the finished preparation and its active pharmaceutical ingredient. FDA said its records did not identify US manufacture of the relevant ingredients for compounding. 1

As an editorial reading aid, keep three identities separate: the platform advertising a product, the facility making the preparation and the manufacturer of its active ingredient. A brand logo on a label does not answer all three questions. 1 2

Why do quality and approval remain separate?

FDA’s broader compounding guidance describes risks such as contamination and incorrect ingredient strength when appropriate standards are not met. The regulator does not review each compounded product for safety, effectiveness and quality before marketing. This explains why a familiar ingredient name is insufficient evidence about a particular preparation. 3

A reader assessing a product claim should ask what the cited evidence actually covers. An ingredient study, a manufacturing statement and a finished-product approval are different kinds of evidence. None should silently stand in for the others; the document needs to support the particular claim being made. 2 3

Is this a final court judgment or a resolved case?

The letter requests a response within 15 working days of receipt. It offers an opportunity to address FDA’s findings; it is not a court judgment or evidence that the case has concluded. 1

FDA notes that subsequent exchanges can change the status of issues described in published warning letters. The source date therefore belongs alongside any summary. This article reports the public documents checked on November 8 and makes no claim to have reviewed nonpublic correspondence. 4

Scope for European readers

This is a dated account of the research or policy described in the linked sources. The stated jurisdiction, study product and population matter. A US or UK announcement does not establish authorisation or availability across Europe. Nothing in this report establishes results for an EPS catalogue material. Read the research-use statement for the storefront's scope.